Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa
Clinical Infectious Diseases · 08.07.2026 · 82 (6) · e1232-e1241
DOI: 10.1093/cid/ciag155 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.03.2026. Verfasst von Jienchi Dorward und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, United Kingdom. Hauptthemen laut MEDLINE: Oxazines, Piperazines, Pyridones, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, UK National Institute of Health and Social Care Research, NIHR.
Abstract (Originalsprache)
Background
Integrase inhibitors, including dolutegravir, may increase risk of major adverse cardiovascular events (MACEs). However, limited data exists from low- and middle-income countries, where tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) has largely replaced tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE).
Methods
We used de-identified data from a South African managed healthcare organization from people with HIV (PWH) without cardiovascular disease, who either initiated TEE or TLD between April 2020 and Dec 2023 (initiation cohort) or were receiving TEE in April 2020 and eligible for TLD (transition cohort). In the initiation cohort, we emulated a target trial using pooled logistic regression models with inverse probability of treatment weights and bootstrapped CIs to compare estimated 3-year MACE risk between TLD versus TEE. In the transition cohort, we used similar methods in 44 emulated monthly sequential trials, comparing MACE risk in people transitioned to TLD with those remaining on TEE.
Results
In the initiation cohort, 7310 PWH initiated TLD (n = 3711) or TEE (n = 3599). Median follow-up was 21 months (IQR 10–33), with 18 MACEs with TLD (3-year risk 0.78%, 95% CI .38–1.11) and 28 with TEE (3-year risk 1.03%, 0.63–1.55; RR 0.75, 0.31–1.30; RD −0.25, −0.94–0.24). In the transition cohort, 22 338 people contributed to 2837 person-trials with TLD and 706 615 with TEE. Median follow-up was 25 months (14–36), with 19 MACEs with TLD (3-year risk 0.97%, 0.52–1.62) and 5420 with TEE (3-year risk 1.17%, 0.99–1.37; RR 0.83, 0.45–1.39; RD −0.20, −0.66–0.44).
Conclusions
Among PWH in South Africa, we found no increased MACE with TLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, United Kingdom.
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
- Health Intelligence Unit, Discovery Health, Johannesburg, Gauteng, South Africa.
- Department of Infectious Disease Epidemiology and International Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
- Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
ORCID-Profile: Jienchi Dorward, Lara Lewis, Kwena Tlhaku, Christian Bottomley
Förderung
- Gates Foundation
- UK National Institute of Health and Social Care Research
- NIHR
Zitieren
APA
Dorward, J., Masombuka, X., Lewis, L., Pastellides, C., van der Molen, J., Asare, K., Tlhaku, K., Brown, J. A., Bottomley, C., Jacobs, D., Collie, S., & Garrett, N. (2026). Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa. Clinical Infectious Diseases, 82(6), e1232-e1241. https://doi.org/10.1093/cid/ciag155
Vancouver
Dorward J, Masombuka X, Lewis L, Pastellides C, van der Molen J, Asare K, et al. Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa. Clinical Infectious Diseases. 2026;82(6):e1232-e1241. doi:10.1093/cid/ciag155
BibTeX
@article{Dorward2026,
author = {Dorward, Jienchi and Masombuka, Xolani and Lewis, Lara and Pastellides, Claudia and van der Molen, Johan and Asare, Kwabena and Tlhaku, Kwena and Brown, Jennifer Anne and Bottomley, Christian and Jacobs, Dave and Collie, Shirley and Garrett, Nigel},
title = {Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {6},
pages = {e1232--e1241},
doi = {10.1093/cid/ciag155}
}
EUVIMED